Abstract:AIM: To study the synergistic effects of calmodulin (CaM) antagonist O-4-ethoxyl-butyl-berbamine (EBB) and pegylated liposomal doxorubicin (PLD) on hepatoma-22 (H-22) in vivo.METHODS: Hepatoma model was established in 50 Balb/c mice by inoculating H-22 cells (2.5x10(6)) subcutaneously into the right backs of the mice. These mice were divided into 5 groups, and treated with saline only, PLD only, doxorubicin (Dox) only, PLD plus EBB and Dox plus EBB, respectively. In the treatment groups, mice were given 5 intravenous of PLD or Dox on days 0, 3, 6, 9 and 12. The first dosage of PLD or Dox was 4.5 mg/kg, the other 4 injections was 1 mg/kg. EBB (5 mg/kg) was coadministered with PLD or Dox in the corresponding groups. The effect of drugs on the life spans of hepatoma-bearing mice and tumor response to the drugs were recorded. Dox levels in the hepatoma cells were measured by a fluorescence assay. Light microscopy was performed to determine the histopathological changes in the major organs of these tumor-bearing mice. The MTT method was used to analyze the effect of Dox or PLD alone, Dox in combination with EBB, or PLD in combination with EBB on the growth of H-22 cells in an in vitro experiment.RESULTS: EBB (5 mg/kg) significantly augmented the antitumor activity of Dox or PLD, remarkably prolonged the median survival time. The median survival time was 18.2 d for control group, but 89.2 d for PLD+EBB group and 70.1 d for Dox+EBB group, respectively. However, Dox alone did not show any remarkable antitumor activity, and the median survival time was just 29.7 d. Addition of EBB to Dox or PLD significantly increased the level of Dox in H-22 cells in vivo. Moreover, EBB diminished liver toxicity of Dox and PLD. In vitro, EBB reduced the IC50 value of Dox or PLD on H-22 cells from 0.050 +/- 0.006 mg/L and 0.054 +/- 0.004 mg/L to 0.012 +/- 0.002 mg/L and 0.013 +/- 0.002 mg/L, respectively (P < 0.01).CONCLUSION: EBB and liposomization could improve the therapeutic efficacy of Dox in liver cancer, while decreasing its liver toxicity.

Combination Treatment of Ergosterol Followed by Amphotericin B Induces Necrotic Cell Death in Human Hepatocellular Carcinoma Cells.

Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy.

Ergosterol peroxide activates Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in human hepatocellular carcinoma cells

Osu-03012, A Novel Celecoxib Derivative, Induces A Unique Autophagy-Like Cell Death In Human Hepatocellular Carcinoma Cells

Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination

Investigating the Mechanisms of Anti-tumoral Effect of Combination Therapy of Calcitriol and Sodium Pentaborate Pentahydrate on HepG2 Hepatocellular Carcinoma Cells

Enhanced Antitumor Activity of Combined Megestrol Acetate and Arsenic Trioxide Treatment in Liver Cancer Cells

Synthesis of Ergosterol Peroxide Conjugates as Mitochondria Targeting Probes for Enhanced Anticancer Activity

The combinational effect of vincristine and berberine on growth inhibition and apoptosis induction in hepatoma cells.

A novel combined resveratrol/berberine phytochemotheraputic using the HePG2 cell line as a model for the treatment of hepatocarcinoma

[Ergosterol peroxide inducing apoptosis of human hepatocellular carcinoma by regulating mitochondrial apoptosis pathway]

Meloxicam Combined With Sorafenib Synergistically Inhibits Tumor Growth Of Human Hepatocellular Carcinoma Cells Via Er Stress-Related Apoptosis

Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways

2-Naphthoic Acid Ergosterol Ester, an Ergosterol Derivative, Exhibits Anti-Tumor Activity by Promoting Apoptosis and Inhibiting Angiogenesis

Combination Treatment of Sorafenib and Bufalin Induces Apoptosis in NCI-H292 Human Lung Cancer Cells In Vitro

Combination of NK-based Immunotherapy and Sorafenib Against Hepatocellular Carcinoma.

Synthesis of 5α,8α‐ergosterol Peroxide 3‐carbamate Derivatives and a Fluorescent Mitochondria‐Targeting Conjugate for Enhanced Anticancer Activities

Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis

The effect mechanism of ergosterol from the nutritional mushroom Leucocalocybe mongolica in breast cancer cells: Protein expression modulation and metabolomic profiling using UHPLC-ESI-Q

Autophagy and Apoptosis in Hepatocellular Carcinoma Induced by EF25-(GSH)2: A Novel Curcumin Analog

Effect of O-4-Ethoxyl-Butyl-Berbamine in Combination with Pegylated Liposomal Doxorubicin on Advanced Hepatoma in Mice